Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment

Octafia, Ita and Sari, Dwi Octamy and Wulandari, Novi and Annisa, Sandra and Wongkar, Linda Wahyuni and Bahari, Ferdias Kurnia and Farikhah, Faiz and Firmansah, Moh and Midhiawati, Erfin and Herawati, Fauna (2021) Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment. Qanun Medika, 5 (1). pp. 35-47. ISSN 2541-2272; e-ISSN: 2548-9526

[thumbnail of Fauna Herawati_Roflumilast.pdf]
Fauna Herawati_Roflumilast.pdf

Download (1MB) | Preview
Official URL / DOI:


Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway inflammation with resulting progressive airflow limitation that has a high incidence, morbidity, and mortality. Roflumilast is an oral phosphodiesterase-4 inhibitor as a therapy to decrease the risk of COPD exacerbations in patients with moderate-severe COPD with a history of chronic bronchitis. Roflumilast can be given orally once daily as a single or combination drug. It can be used as COPD moderate-severe but also more beneficial as COPD mild treatment. The efficacy of Roflumilast can prevent exacerbations of repetition and can fixed lung function both in terms of FEV1 and vital capacity to force. The incidence of side effects, which are diarrhea and digestive disorders. The cost-effectiveness showed that Quality of life patient with Roflumilast is better than the group without additional. This paper aimed to review systematically Roflumilast as COPD treatment for the clinical application.

Item Type: Article
Uncontrolled Keywords: COPD, Roflumilast, phosphodiesterase-4 inhibitor
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy > Department of Pharmacy
Depositing User: Ester Sri W. 196039
Date Deposited: 26 Jan 2021 07:15
Last Modified: 26 Jan 2021 07:15

Actions (login required)

View Item View Item